home / stock / vtgn / vtgn news

VTGN News and Press, VistaGen Therapeutics Inc. From 03/28/19

Stock Information
Company Name: VistaGen Therapeutics Inc.
Stock Symbol: VTGN
Market: NASDAQ
Website: vistagen.com
Menu
VTGN VTGN Quote VTGN Short VTGN News VTGN Articles VTGN Message Board
Get VTGN Alerts

News, Short Squeeze, Breakout and More Instantly...
VTGN - VistaGen Therapeutics Receives Australian Patent for Treatment of Depression with AV-101

SOUTH SAN FRANCISCO, CA / ACCESSWIRE / March 28, 2019 / VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression, social anxiety disorder and other central nervous system (CNS) diseases and disorders with high unm...
VTGN - Vistgen And Relmada: Competitors In Depression Treatment

In 2017 researchers from the University of Oxford's Department of Psychiatry proclaimed no new antidepressants would likely come to market in the next decade. Despite this lousy prediction, March 2019 saw the approval of Johnson & Johnson's ( JNJ ) esketamine (Spravato) for treatment...

VTGN - VistaGen Therapeutics (VTGN) Investor Presentation - Slideshow

The following slide deck was published by VistaGen Therapeutics, Inc. in conjunction with this Read more ...

VTGN - VistaGen Therapeutics to Present at the Oppenheimer 29th Annual Healthcare Conference on March 19, 2019

SOUTH SAN FRANCISCO, CA / ACCESSWIRE / March 14, 2019 / VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) diseases and disorders with high unmet need, today announced th...
VTGN - VistaGen Therapeutics Receives Notice of Allowance for Additional U.S. Patent Regarding Methods of Production for AV-101

SOUTH SAN FRANCISCO, CA / ACCESSWIRE / March 13, 2019 / VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) diseases and disorders with high unmet need, today announced th...

VTGN - VistaGen Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference on March 13, 2019

SOUTH SAN FRANCISCO, CA / ACCESSWIRE / March 7, 2019 / VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression, social anxiety disorder and other central nervous system (CNS) diseases and disorders with high unmet ...

VTGN - Four Tech Stocks Looking To Test February Highs

CORAL GABLES, FL / ACCESSWIRE / February 27, 2019 / Nothing in life is guaranteed, but based on the first few months of the year, the future of the tech stock market looks to be in good shape. Driven by the activity in the tech industry, companies in the space have demonstrated in 2019 tha...
VTGN - Microcaps tops midday movers

Gainers:  FTE Networks (NYSEMKT: FTNW ) +123% . Telaria (NYSE: TLRA ) +35% . Ferroglobe PLC (NASDAQ: GSM ) +27% . EverQuote (NASDAQ: EVER ) +26% . Vitamin Shoppe (NYSE: VSI ) +25% . Heidrick & Struggles International (NASDAQ: HSII ) +24% . Key Energy Services (NYSE: KEG ) +...

VTGN - TRXC, MEDP and SAGE among premarket losers

VistaGen Therapeutics (NASDAQ: VTGN )  -23%  on announcing stock offering. More news on: VistaGen Therapeutics, Inc., TransEnterix, Inc., China Internet Nationwide Financial Services Inc., Stocks on the move, Read more ...

VTGN - VistaGen Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2019 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) diseases and disorders with high unmet need, today anno...
Previous 10 Next 10